MMIT (Managed Markets Insight & Technology)’s Post

In BioPharma Dive, MMIT’s Carolyn Zele explains how real-world data can help oncology manufacturers improve access to their therapies: https://ow.ly/oZeO50QxSWJ. #Oncology #RWD #RealWorld #RealWorldData

LARVOL closely monitors market trends and regulatory changes to evaluate upcoming PDUFA (Prescription Drug User Fee Act) dates for oncology products. Download your copy today and discover our product PULSE (Market Intelligence): https://bit.ly/4canQRC #LARVOL #Oncology #CancerResearch #PDUFA #LARVOLPulse

LARVOL actively tracks market trends and regulatory shifts to assess upcoming PDUFA (Prescription Drug User Fee Act) dates for oncology products. Get your copy today and explore our product PULSE (Market Intelligence) 👉 https://bit.ly/4canQRC #LARVOL #Oncology #CancerResearch #PDUFA #LARVOLPulse

Want to know how the FDA’s Project Optimus is reshaping oncology drug development? Check out our blog post for real-world case studies and industry impacts! https://hubs.ly/Q02CJ5vr0 #Oncology #DrugDevelopment #ProjectOptimus

LARVOL closely monitors market trends and regulatory changes to evaluate upcoming PDUFA (Prescription Drug User Fee Act) dates for oncology products. Download your copy now and discover our PULSE (Market Intelligence) tool 👉 https://bit.ly/4canQRC #LARVOL #Oncology #CancerResearch #PDUFA #LARVOLPulse

Are you ready to accelerate your #oncology trial and get your product to market? Over 12 months, IQVIA successfully supported 11 oncology market approvals. If you'd like to learn how we can help support your oncology trial, visit our webpage: https://bit.ly/3STEmPS #oncology #clinicaltrials

The editorial "Moving the Needle for Oncology Dose Optimization: A Call for Action" highlights the importance of adaptive dosing strategies to improve treatment efficacy and patient outcomes in oncology. This aligns with our mission at Baysient, where our TuMinimize™ software ensures precise and personalized dosing for oncology biologics. 📖 Read the full article here: https://bit.ly/3zpAL4K #Oncology #DoseOptimization #HealthTech #PersonalizedMedicine

Starting January 2025, the European Union’s Joint Clinical Assessment (JCA) is set to transform the market access landscape for oncology and advanced therapy medicinal products (ATMP). At Putnam, we’re ready to guide you through these changes with tailored strategies that ensure your success. With our strategic planning, market access roadmaps, and patient-centered outcomes expertise, your product will be positioned for success. Connect with us to learn more about how our JCA offerings can help you thrive in this evolving landscape: https://lnkd.in/eS55xEbc #JCA #MarketAccess #Oncology #RegulatoryStrategy

Launching a biopharma product means high stress and a lot at stake. The investment is significant and there are patients waiting for life-changing treatments. And for conditions requiring diagnostic testing, launches can be even more complex. The last thing you and your company need during the chaotic launch time is to be caught in a #biopharmablunder. Don’t miss this quick clip featuring DKP expert Marysia Cole to learn more. #druglaunch #payers #raredisease #cellandgenetherapy #oncology #diagnostictesting

Recent #oncology launches have faced significant challenges, particularly for small to mid-size manufacturers. Limited internal resources and financing hinder today’s innovators from executing concurrent planning and strategic development and assuming the risk on their own to ensure the successful commercialization of their lifesaving product. Read EVERSANA’s Oncology experts’ latest article to learn what you should be asking to overcome these challenges and bolster your commercialization strategy: https://ow.ly/eN7l50QRo2g